MultiVir withdraws IPO; RapidMist buccal delivery tech finds partner;

> Cancer gene therapy company MultiVir withdrew its $60 million IPO. More

> Generex is collaborating with NHTherapeutics. The companies will utilize Generex's RapidMist buccal delivery technology to deliver Leuprolide for the treatment of hypogonadism and other endocrine disorders. More

Suggested Articles

Purdue's reformulated OxyContin may stop patients from snorting or injecting the drug, but it doesn't curb abuse overall, an FDA panel determined.

Roche is gearing up to launch an eye implant to make its Lucentis AMD drug easier to use. But the drugmaker has even bigger plans for the device.

Delivery specialist IntelGenx struck two deals to develop oral films for prescription psychedelics this summer with Canada's Cybin and ATAI.